Mark Schoenberg, Chief Medical Officer, on May 08, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $300,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 134,985 ordinary shares of the company, with 134,985 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1668243/000143774926016104/xslF345X05/rdgdoc.xml
Price: $31.50, Change: $+2.10, Percent Change: +7.14%
Trent G Kamke, Senior Vice President, Operations, on May 08, 2026, sold 2,928 shares in Lemaitre Vascular (LMAT) for $313,287. Following the Form 4 filing with the SEC, Kamke has control over a total of 3,749 common shares of the company, with 3,749 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1158895/000119312526217113/xslF345X05/ownership.xml
Kurtis Joseph Binder, CFO, on May 08, 2026, sold 65,000 shares in Arlo Technologies (ARLO) for $1,020,474. Following the Form 4 filing with the SEC, Binder has control over a total of 499,885 common shares of the company, with 499,885 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1736946/000165473726000011/xslF345X05/form4-05112026_090526.xml
Lawrence J Jasinski, Director, on May 07, 2026, sold 3,943 shares in Lemaitre Vascular (LMAT) for $433,730. Following the Form 4 filing with the SEC, Jasinski has control over a total of 4,714 common shares of the company, with 4,714 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1158895/000119312526217096/xslF345X05/ownership.xml